ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Smoking Cessation Training Follows Doctors Into Practice

October 29, 2004

Arbuck Leaves NCI to Guide BMS Oncology Pipeline.

September 7, 2001

Army Accepting Letters of Intent For Research in Breast Cancer; Plans Announcement In Sept.

July 16, 1993

New Drug Combination Shrinks Kidney Cancers

June 30, 2006

NCI Programs: Coleman To Lead NCI’s New Radiation Oncology Program

February 5, 1999

In Brief: Indiana U. Planning “World Class” Cancer Center; UCLA Names Two New Cancer Control Directors

June 6, 1986